MINISTRY-OF-HAJJ-UMRAH
27.12.2022 13:16:42 CET | Business Wire | Press release
Under the patronage of H.R.H Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques and Governor of Makkah Region, the Ministry of Hajj and Umrah will be organizing the ‘Hajj Expo 2023’ conference and exhibition, on 9-12 January 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221227005098/en/
His Royal Highness Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques, Governor of Makkah Region (Photo: AETOSWire)
The four-day event is part of the Ministry's ongoing efforts to build an innovative ecosystem of services and solutions to better serve pilgrims at the Two Holy Mosques, while enhancing their religious and cultural experiences. It aims to create an integrated and sustainable ecosystem that improves pilgrims’ experiences, anticipate their future trends, and establish opportunities for further collaborations, agreements, and local and international initiatives.
H.E. Minister of Hajj and Umrah, Dr. Tawfiq bin Fawzan Al-Rabiah, said: “The conference will allow entrepreneurs, innovators, and researchers from more than 200 global organizations to share successful experiences, and brainstorm sustainable quality solutions designed to cater to pilgrims’ aspirations and needs. This reflects the unrelenting support dedicated by the Custodian of the Two Holy Mosques, and HH the Crown Prince to the Hajj and Umrah sector, in line with the Saudi Vision 2030.”
With delegations from over 56 countries, ‘Expo Hajj’ is expected to witness the signing of 400 agreements and partnerships. It will feature 10 keynote sessions, 13 panel discussions and ‘Hajj Talks’, as well as 36 workshops and related events and activities, notably the Islamic exposition and the ‘Hajj Hackathon’.
‘Hajj Expo 2023’ will be sponsored by several entities and companies, including Kidana Development Company, Elm, Al Wukalla Company, Catering Contractors Association, Muslim World League, Rua AlMadinah Holding, Motawifs Pilgrims for Southeast Asian Countries Co., Alrajhi Umrah, Dallah Albaraka Holding, Sadu Business Solutions, The Company for Cooperative Insurance (Tawuniya), and Saudi Arabia Railways (SAR), Saudi Public Transport Company (SAPTCO), Mohamed Yousuf Naghi Motors Co., Flynas, Saudi Al-Qaid Transportation Co., Alif Alif FM, High Point Technology Company, and Casablanca Company for Hotel & Touristic Services Co. LTD.
The 2021 edition of the conference saw record numbers with +45,000 attendees and 115 commercial agreements. The second edition will feature a wide range of scientific sessions, workshops, and training programs, with several ministers of Islamic affairs, endowments and Hajj ambassadors and consuls, and Hajj and Umrah operators from around the world.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom